Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease

Blood

Volumn 123, Issue 3, 2014, Pages 377-390

  Belcher, John D ^a   Chen, Chunsheng ^a   Nguyen, Julia ^a   Milbauer, Liming ^a   Abdulla, Fuad ^a   Alayash, Abdu I ^b   Smith, Ann ^c   Nath, Karl A ^d   Hebbel, Robert P ^a   Vercellotti, Gregory M ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; BLOCKING ANTIBODY; CD31 ANTIGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HAPTOGLOBIN; HEME; HEMOGLOBIN; HEMOPEXIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; INTERCELLULAR ADHESION MOLECULE 1; LIPOPOLYSACCHARIDE; METHEMOGLOBIN; METHYLENE BLUE; OXIDIZING AGENT; PADGEM PROTEIN; PROTEIN KINASE C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RESATORVID; TOLL LIKE RECEPTOR 4; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4; VITRONECTIN RECEPTOR; VON WILLEBRAND FACTOR; NFKB1 PROTEIN, MOUSE; TLR4 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL OCCLUSION; BLOOD VESSEL WALL; CELL ACTIVATION; CONTROLLED STUDY; DEGRANULATION; ENZYME INHIBITION; INTRAVASCULAR HEMOLYSIS; LETHALITY; LEUKOCYTE ADHERENCE; LEUKOCYTE ROLLING; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SIGNAL TRANSDUCTION; STEADY STATE; TRANSCRIPTION INITIATION; UMBILICAL VEIN ENDOTHELIAL CELL; WEIBEL PALADE BODY; ANIMAL; BONE MARROW CELL; C57BL MOUSE; CELL ADHESION; CHEMISTRY; CYTOLOGY; ENDOTHELIUM CELL; HEMOLYSIS; HUMAN; INFLAMMATION; METABOLISM; OXIDATIVE STRESS; PHENOTYPE; TRANSGENIC MOUSE; VASOCONSTRICTION;

ANEMIA, SICKLE CELL; ANIMALS; BONE MARROW CELLS; CELL ADHESION; ENDOTHELIAL CELLS; HAPTOGLOBINS; HEME; HEMOGLOBINS; HEMOLYSIS; HEMOPEXIN; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NF-KAPPA B P50 SUBUNIT; OXIDATIVE STRESS; PHENOTYPE; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; VASOCONSTRICTION; VON WILLEBRAND FACTOR;

EID: 84894567032     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-04-495887     Document Type: Article

References (55)

1. Graça-Souza AV, Arruda MA, de Freitas MS, Barja-Fidalgo C, Oliveira PL. Neutrophil activation by heme: implications for inflammatory processes. Blood. 2002;99(11):4160-4165. (Pubitemid 35332061)
2. Porto BN, Alves LS, Fernández PL, et al. Heme induces neutrophil migration and reactive oxygen species generation through signaling pathways characteristic of chemotactic receptors. J Biol Chem. 2007;282(33):24430-24436. (Pubitemid 47328067)
3. Wagener FA, Volk HD, Willis D, et al. Different faces of the heme-heme oxygenase system in inflammation. Pharmacol Rev. 2003;55(3): 551-571. (Pubitemid 37013215)
4. Figueiredo RT, Fernandez PL, Mourao-Sa DS, et al. Characterization of heme as activator of Toll-like receptor 4. J Biol Chem. 2007;282(28): 20221-20229. (Pubitemid 47100035)
5. Kaul DK, Hebbel RP. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest. 2000;106(3):411-420. (Pubitemid 30655641)
6. Belcher JD, Marker PH, Weber JP, Hebbel RP, Vercellotti GM. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood. 2000; 96(7):2451-2459.
7. Belcher JD, Bryant CJ, Nguyen J, et al. Transgenic sickle mice have vascular inflammation. Blood. 2003;101(10):3953-3959. (Pubitemid 36857872)
8. Wood KC, Hebbel RP, Granger DN. Endothelial cell P-selectin mediates a proinflammatory and prothrombogenic phenotype in cerebral venules of sickle cell transgenic mice. Am J Physiol Heart Circ Physiol. 2004;286(5):H1608-H1614. (Pubitemid 38525445)
9. Ballas SK, Marcolina MJ. Hyperhemolysis during the evolution of uncomplicated acute painful episodes in patients with sickle cell anemia. Transfusion. 2006;46(1):105-110. (Pubitemid 43381792)
10. Reiter CD, Wang X, Tanus-Santos JE, et al. Cellfree hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002;8(12): 1383-1389. (Pubitemid 36019423)
11. Belcher JD, Beckman JD, Balla G, Balla J, Vercellotti G. Heme degradation and vascular injury. Antioxid Redox Signal. 2010;12(2): 233-248.
12. Balla J, Jacob HS, Balla G, Nath K, Eaton JW, Vercellotti GM. Endothelial-cell heme uptake from heme proteins: induction of sensitization and desensitization to oxidant damage. Proc Natl Acad Sci U S A. 1993;90(20):9285-9289. (Pubitemid 23315768)
13. Morgan WT, Muster P, Tatum F, Kao SM, Alam J, Smith A. Identification of the histidine residues of hemopexin that coordinate with heme-iron and of a receptor-binding region. J Biol Chem. 1993; 268(9):6256-6262. (Pubitemid 23099317)
14. Fabry ME, Nagel RL, Pachnis A, Suzuka SM, Costantini F. High expression of human beta S- and alpha-globins in transgenic mice: hemoglobin composition and hematological consequences. Proc Natl Acad Sci U S A. 1992; 89(24):12150-12154. (Pubitemid 23004803)
15. Wu LC, Sun CW, Ryan TM, Pawlik KM, Ren J, Townes TM. Correction of sickle cell disease by homologous recombination in embryonic stem cells. Blood. 2006;108(4):1183-1188. (Pubitemid 44232013)
16. Belcher JD, Nath KA, Vercellotti GM. Vasculotoxic and pro-inflammatory effects of plasma heme: cell signaling and cytoprotective responses. ISRN Oxid Med. 2013;2013:831596.
17. Belcher JD, Mahaseth H, Welch TE, Otterbein LE, Hebbel RP, Vercellotti GM. Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. J Clin Invest. 2006;116(3): 808-816. (Pubitemid 43326890)
18. Huy NT, Xuan Trang DT, Uyen DT, Sasai M, Harada S, Kamei K. An improved colorimetric method for quantitation of heme using tetramethylbenzidine as substrate. Anal Biochem. 2005;344(2):289-291. (Pubitemid 41208143)
19. Hebbel RP, Vercellotti GM, Pace BS, et al. The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice. Blood. 2010;115(12):2483-2490.
20. Kohli DR, Li Y, Khasabov SG, et al. Pain-related behaviors and neurochemical alterations in mice expressing sickle hemoglobin: modulation by cannabinoids. Blood. 2010;116(3):456-465.
21. Bahl N, Winarsih I, Tucker-Kellogg L, Ding JL. Extracellular haemoglobin upregulates and binds to tissue factor on macrophages: implications for coagulation and oxidative stress. Thromb Haemost. 2013;111(1).
22. Belcher JD, Mahaseth H, Welch TE, et al. Critical role of endothelial cell activation in hypoxiainduced vasoocclusion in transgenic sickle mice. Am J Physiol Heart Circ Physiol. 2005;288(6): H2715-H2725. (Pubitemid 40720650)
23. Carmody RJ, Chen YH. Nuclear factor-kappaB: activation and regulation during toll-like receptor signaling. Cell Mol Immunol. 2007;4(1):31-41.
24. Minneci PC, Deans KJ, Zhi H, et al. Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin. J Clin Invest. 2005;115(12):3409-3417. (Pubitemid 43121829)
25. Bunn HF, Jandl JH. Exchange of heme among hemoglobins and between hemoglobin and albumin. J Biol Chem. 1968;243(3):465-475.
26. Wendel WB. The control of methemoglobinemia with methylene blue. J Clin Invest. 1939;18(2): 179-185.
27. Brittain JE, Knoll CM, Ataga KI, Orringer EP, Parise LV. Fibronectin bridges monocytes and reticulocytes via integrin alpha4beta1. Br J Haematol. 2008;141(6):872-881. (Pubitemid 351724851)
28. Embury SH, Matsui NM, Ramanujam S, et al. The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in vivo. Blood. 2004;104(10):3378-3385. (Pubitemid 39507162)
29. Kaul DK, Liu XD, Zhang X, et al. Peptides based on alphaV-binding domains of erythrocyte ICAM-4 inhibit sickle red cell-endothelial interactions and vaso-occlusion in the microcirculation. Am J Physiol Cell Physiol. 2006;291(5):C922-C930. (Pubitemid 44771811)
30. Turhan A, Weiss LA, Mohandas N, Coller BS, Frenette PS. Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci U S A. 2002;99(5):3047-3051. (Pubitemid 34240583)
31. Wick TM, Moake JL, Udden MM, Eskin SG, Sears DA, McIntire LV. Unusually large von Willebrand factor multimers increase adhesion of sickle erythrocytes to human endothelial cells under controlled flow. J Clin Invest. 1987;80(3):905-910. (Pubitemid 18003966)
32. Valentijn KM, Sadler JE, Valentijn JA, Voorberg J, Eikenboom J. Functional architecture of Weibel- Palade bodies. Blood. 2011;117(19):5033-5043.
33. Wood KC, Hebbel RP, Granger DN. Endothelial cell NADPH oxidase mediates the cerebral microvascular dysfunction in sickle cell transgenic mice. FASEB J. 2005;19(8):989-991. (Pubitemid 40827727)
34. Matsunaga N, Tsuchimori N, Matsumoto T, Ii M. TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules. Mol Pharmacol. 2011;79(1):34-41.
35. Gladwin MT, Kato GJ, Weiner D, et al; DeNOVO Investigators. Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. JAMA. 2011;305(9): 893-902.
36. Jison ML, Munson PJ, Barb JJ, et al. Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease. Blood. 2004;104(1):270-280. (Pubitemid 38879868)
37. Muller-Eberhard U, Javid J, Liem HH, Hanstein A, Hanna M. Plasma concentrations of hemopexin, haptoglobin and heme in patients with various hemolytic diseases. Blood. 1968;32(5):811-815.
38. Hebbel RP, Morgan WT, Eaton JW, Hedlund BE. Accelerated autoxidation and heme loss due to instability of sickle hemoglobin. Proc Natl Acad Sci U S A. 1988;85(1):237-241. (Pubitemid 18055323)
39. Chen J, Hobbs WE, Le J, Lenting PJ, de Groot PG, López JA. The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma. Blood. 2011; 117(13):3680-3683.
40. Zhou Z, Yee DL, Guchhait P. Molecular link between intravascular hemolysis and vascular occlusion in sickle cell disease. Curr Vasc Pharmacol. 2012;10(6):756-761.
41. Kristiansen M, Graversen JH, Jacobsen C, et al. Identification of the haemoglobin scavenger receptor. Nature. 2001;409(6817):198-201. (Pubitemid 32144285)
42. Schaer DJ, Buehler PW, Alayash AI, Belcher JD, Vercellotti GM. Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood. 2013;121(8):1276-1284.
43. Tolosano E, Fagoonee S, Morello N, Vinchi F, Fiorito V. Heme scavenging and the other facets of hemopexin. Antioxid Redox Signal. 2010;12(2): 305-320.
44. Hanson MS, Piknova B, Keszler A, et al. Methaemalbumin formation in sickle cell disease: effect on oxidative protein modification and HO-1 induction. Br J Haematol. 2011;154(4):502-511.
45. Smith A, Morgan WT. Haem transport to the liver by haemopexin. Receptor-mediated uptake with recycling of the protein. Biochem J. 1979;182(1): 47-54. (Pubitemid 9240663)
46. Hvidberg V, Maniecki MB, Jacobsen C, Højrup P, Møller HJ, Moestrup SK. Identification of the receptor scavenging hemopexin-heme complexes. Blood. 2005;106(7):2572-2579. (Pubitemid 41510836)
47. Vinchi F, De Franceschi L, Ghigo A, et al. Hemopexin therapy improves cardiovascular function by preventing heme-induced endothelial toxicity in mouse models of hemolytic diseases. Circulation. 2013;127(12): 1317-1329.
48. Li RC, Saleem S, Zhen G, et al. Heme-hemopexin complex attenuates neuronal cell death and stroke damage. J Cereb Blood Flow Metab. 2009; 29(5):953-964.
49. Larsen R, Gozzelino R, Jeney V, et al. A central role for free heme in the pathogenesis of severe sepsis. Sci Transl Med. 2010;2(51):51ra71.
50. Takano M, Meneshian A, Sheikh E, et al. Rapid upregulation of endothelial P-selectin expression via reactive oxygen species generation. Am J Physiol Heart Circ Physiol. 2002;283(5): H2054-H2061. (Pubitemid 35217041)
51. Park HS, Jung HY, Park EY, Kim J, Lee WJ, Bae YS. Cutting edge: direct interaction of TLR4 with NAD(P)H oxidase 4 isozyme is essential for lipopolysaccharide-induced production of reactive oxygen species and activation of NF-kappa B. J Immunol. 2004;173(6):3589-3593. (Pubitemid 39280716)
52. George A, Pushkaran S, Konstantinidis DG, et al. Erythrocyte NADPH oxidase activity modulated by Rac GTPases, PKC, and plasma cytokines contributes to oxidative stress in sickle cell disease. Blood. 2013;121(11):2099-2107.
53. Ghosh S, Adisa OA, Chappa P, et al. Extracellular hemin crisis triggers acute chest syndrome in sickle mice. J Clin Invest. 2013.
54. Zannettino AC, Holding CA, Diamond P, et al. Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol. 2005; 204(2):714-723. (Pubitemid 40934668)
55. Dauphinee SM, Karsan A. Lipopolysaccharide signaling in endothelial cells. Lab Invest. 2006; 86(1):9-22. (Pubitemid 43250964)